Search results for: Pricing and Reimbursement
Filter search results
Around The World in HTAs: France – Three Core HTA Values
12 March 2026
…European HTA regulation (HTAR). The Haute Autorité de Santé (HAS) is responsible for the technology assessment, with its opinions informing reimbursement and pricing decisions. In most cases, reimbursement decisions are overseen by the MoH,…
Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape
24 September 2025
…Arabia requires navigating several steps: market authorisation, pricing, HTA, and reimbursement or procurement. Market authorisation is granted nationally by the Saudi Food and Drug Authority (SFDA), with four distinct approval…
Looking Further Afield – What Can Health Economics Learn from the Environmental Economics Approach to Discounting?
1 February 2024
…Limits to Substitution Between Ecosystem Services and Manufactured Goods and Implications for Social Discounting. Environmental and Resource Economics, 69(1), pp.135–158. 10.1007/s10640-016-0068-5. Freeman, M., Groom, B. and Spackman, M., 2018. Social…
The Trump Administration’s US Drug Pricing Proposal – What will happen next?
12 June 2025
…and design of the US healthcare system. This complexity is multi-factorial, with its mix of public and private providers, insurers and funders, and the multiple stakeholders and intermediaries involved in…
New research reveals, in carers’ own words, the multidimensional burden of caring for leukemia patients
20 November 2025
…and US, and 5 each from France, Germany, Italy and Spain – were asked questions about the patient’s diagnosis and how they became a carer, their experience of caregiving as…
The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
2 June 2023
…consider i) pricing and reimbursement mechanisms, ii) standardising testing and care pathways, and iii) developing new infrastructure Share this: Download publication Next-generation sequencing (NGS) generates comprehensive and actionable information on…
Spotlight on OHE: Value Based Pricing and New Technologies
31 December 2012
…presentation (see below) discussed methods and processes for coordinating the assessment of diagnostics and treatments and urged that a consistent approach be developed and implemented. This was based in part…
Payment Models for Multi-Indication Therapies
1 November 2021
…Available from https://www.ohe.org/publications/multi-indication-pricing-mip-practical-solutions-and-steps-move-forward. Towse, A., Cole, A., and Zamora, B. (2018) The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries. OHE Consulting Report. Available from https://www.ohe.org/publications/debate-indication-based-pricing-us-and-five-major-european-countries….
A global landscape analysis of access to tumour-agnostic therapies
1 December 2025
…TA therapies – pembrolizumab, larotrectinib, and entrectinib – to assess regulatory, health technology assessment (HTA), and reimbursement outcomes and identify barriers and possible solutions along the access pathway. The key…